Comparison of CD68 and CD163 IHC expression in training and validation cohorts, in EBER+ and EBER− cases, and selected subtypes of CHL in the entire cohort
| . | n . | CD68 expression . | CD163 expression . | ||||
|---|---|---|---|---|---|---|---|
| Median . | Range . | P . | Median . | Range . | P . | ||
| Training | 143 | 10.6 | 2.7-57.4 | .91 | 13.0 | 0.4-79.5 | .48 |
| Validation | 144 | 10.5 | 2.4-51.8 | 13.5 | 0.4-79.1 | ||
| EBER+ | 49 | 15.7 | 3.1-57.4 | < .01 | 29.9 | 1.5-79.5 | < .01 |
| EBER− | 238 | 9.6 | 2.4-37.2 | 11.1 | 0.4-79.1 | ||
| Nodular sclerosis | 223 | 9.6 | 2.7-51.8 | < .01 | 10.9 | 0.4-79.1 | < .01 |
| Mixed cellularity | 38 | 16.1 | 2.8-57.4 | 28.9 | 0.4-79.5 | ||
| Lymphocyte rich | 8 | 7.1 | 2.8-26.7 | 8.9 | 1.4-41.4 | ||
| . | n . | CD68 expression . | CD163 expression . | ||||
|---|---|---|---|---|---|---|---|
| Median . | Range . | P . | Median . | Range . | P . | ||
| Training | 143 | 10.6 | 2.7-57.4 | .91 | 13.0 | 0.4-79.5 | .48 |
| Validation | 144 | 10.5 | 2.4-51.8 | 13.5 | 0.4-79.1 | ||
| EBER+ | 49 | 15.7 | 3.1-57.4 | < .01 | 29.9 | 1.5-79.5 | < .01 |
| EBER− | 238 | 9.6 | 2.4-37.2 | 11.1 | 0.4-79.1 | ||
| Nodular sclerosis | 223 | 9.6 | 2.7-51.8 | < .01 | 10.9 | 0.4-79.1 | < .01 |
| Mixed cellularity | 38 | 16.1 | 2.8-57.4 | 28.9 | 0.4-79.5 | ||
| Lymphocyte rich | 8 | 7.1 | 2.8-26.7 | 8.9 | 1.4-41.4 | ||